Margetuximab: An Updated Review of its Clinical Pharmacology and Therapeutic Advances
International Journal of Innovative Science and Research Technology · 17.08.2026 · 565
DOI: 10.38124/ijisrt/26aug244 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Innovative Science and Research Technology, online erschienen am 17.08.2026. Verfasst von Deepika A. und 1 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Margetuximab is a new chimeric IgG1 monoclonal antibody designed to enhance antitumor activity in the immune system and treat patients with HER2-positive malignant disease. Margetuximab selectively binds to activate the Fcγ receptor CD16A and shows reduced binding to inhibitory Fcγ receptor CD32B, thereby enhancing antibody-dependent cellular cytotoxicity (ADCC) and providing greater therapeutic potential than conventional HER2-targeted antibodies. This review covers the discovery, physicochemical properties, pharmacokinetic properties, mechanism of action, synthesis, and clinical applications of margetuximab. Furthermore, this review covers evidence of its efficacy, safety profile, adverse effects, drug interactions, contraindications, conventional formulations, emerging formulations, and patents. The efficacy of margetuximab in combination with chemotherapy in clinical studies suggests it is a useful treatment option in the metastatic setting for patients with HER2-positive breast cancer who have failed previous anti-HER2 treatment, have a manageable toxicity profile, and have improved immune-mediated antitumor responses. Moreover, continuous clinical research and formulation strategy development are ongoing to further advance its therapeutic applications. Overall, margetuximab represents a significant improvement in HER2-targeted therapy, and further studies are likely to enhance its clinical effectiveness and expand its potential applications in precision oncology.
Zitieren
APA
A., D., & G., A. (2026). Margetuximab: An Updated Review of its Clinical Pharmacology and Therapeutic Advances. International Journal of Innovative Science and Research Technology, 565. https://doi.org/10.38124/ijisrt/26aug244
Vancouver
A. D, G. A. Margetuximab: An Updated Review of its Clinical Pharmacology and Therapeutic Advances. International Journal of Innovative Science and Research Technology. 2026:565. doi:10.38124/ijisrt/26aug244
BibTeX
@article{A2026,
author = {A., Deepika and G., Ariharasivakumar},
title = {Margetuximab: An Updated Review of its Clinical Pharmacology and Therapeutic Advances},
journal = {International Journal of Innovative Science and Research Technology},
year = {2026},
pages = {565},
doi = {10.38124/ijisrt/26aug244}
}
EUVIMED